

Please type a plus sign (+) inside this box

PTO/SB/21 (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

09/441,318

Filing Date

November 16, 1999

First Named Inventor

Conklin et al

Group Art Unit

1638

Examiner Name

Kubelik, A.

8

Attorney Docket Number

BTI-41

JUN 2 2 2001

TECH CENTER 1600 2000

RECEIVED

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Checklist and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> To Convert a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	Sequence List sequence List Disk Statement Under 37 CFR 1.821 (f)-(g)
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Brown & Michaels, PC

Signature

Date

6/13/01

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 70 6934000 1247141846

Typed or printed name

Judy H. Barron

Signature

Date

6-13-01

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUN 22 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE TECH CENTER 1600/2900

June 13, 2001

In re Application of: Conklin *et al.*
Serial No. 09/441,318
Filed: November 16, 1999
For: TRANSGENIC PLANT WITH INCREASED EXPRESSION OF GDP-MANNOSE PYROPHOSPHORYLASE
Examiner: Kubelik, Anne R.
Art Unit: 1638
Attorney Docket No.: BTI-41

PRELIMINARY AMENDMENT

HONORABLE COMMISSIONER OF
PATENTS AND TRADEMARKS
Washington, D.C. 20231

Please amend the above-identified application as follows:

In the Specification:

Please delete the third paragraph on page 5, at lines 6-8, which refers to Fig. 5.

Please replace the second complete paragraph at page 7, lines 16-22, with the following replacement paragraph:

To test the hypothesis that *vtc1-1* and *vtc1-2* harbor mutations in the GDP-mannose pyrophosphorylase gene, the potential for mutations in the pyrophosphorylase genomic sequence derived from each of these mutant alleles was examined. The sequences of both *vtc1-1* and *vtc1-2* contain the identical single cytosine to thymine point mutation at position +64 relative to the first base of the presumed initiator methionine (Figure 3D). This predicted missense mutation would convert a highly conserved proline to a serine at amino acid 22 in the GDP-mannose pyrophosphorylase amino acid sequence.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited in the U.S. Postal Service as Certified Mail No: 7093400001247141846 with a return receipt requested, in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on June 13, 2001.

Judy H. Barron